Standout Papers

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, ... 2008 2026 2014 2020 509
  1. Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 (2008)
    Dana D. Hu‐Lowe, Helen Y. Zou et al. Clinical Cancer Research

Citation Impact

3 by Nobel laureates 2 from Science/Nature 57 standout
Sub-graph 1 of 22

Citing Papers

Renal cell carcinoma
2024 Standout
Photon-Controlled Pyroptosis Activation (PhotoPyro): An Emerging Trigger for Antitumor Immune Response
2023 Standout
6 intermediate papers

Works of Xinglin Wu being referenced

Pharmacokinetics, Metabolism, and Excretion of [14C]Axitinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Humans
2014
Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
2008 Standout

Author Peers

Author Molecular Biology Infectious Diseases Surgery PRM Oncology Last Decade Papers Cites
Xinglin Wu 403 155 31 284 257 25 939
Chou Srey 79 19 3 2 13 717
G. T. Noel 16 312
Raudel Sandoval 499 11 53 66 137 15 993
Paul Zaszczurynski 5 137 11 1 19 397
Vitruvius 3 70

All Works

Loading papers...

Rankless by CCL
2026